Analyst Upgrades

• General Growth (GGP) to outperform from neutral at Credit Suisse.
• PPL Corp. (PPL) to outperform from market perform at FBR Capital.
• Hudson City Bancorp (HCBK) to neutral from reduce at Nomura.
• Hologic (HOLX) to conviction buy from buy at Goldman.
• Cognex (CGNX) to overweight from neutral at Piper Jaffray.
• Buckeye Partners (BPL) to outperform from market perform at Wells Fargo.
• Ericsson (ERIC) and Health Care REIT (HCN) to buy from neutral and Olin (OLN) to neutral from sell at UBS.
• Nalco (NLC) to overweight from neutral at JPMorgan.
• Watts Water (WTS) to buy from hold at BB&T.
• McDermott (MDR) to buy from neutral at Pritchard.

Betting on the outcome of a buyout is no easy feat. Will there be a heated auction? Or will the bidders have doubts and want price concessions?

The result is often much volatility. Just look at Beckman Coulter (BEC), a top medical diagnostic instruments company. In early December, the company put itself up for sale and the stock price surged to $72. Since then, the shares have traded in band of $71 to $75.

Because of the complexities of its business, it can be difficult to decipher whether the Blackstone Group (BX) has posted a profit. In its latest earnings report, there was a net loss of $11 million, or $0.03 per share, up from a loss of $143.3 million in the same period a year ago.

But private equity firms highlight another metric: economic net income. It's supposed to be a better reflection of the earnings. According to this, Blackstone saw a 46% rise to $0.29 per share in profits.

As the economy rebounds and credit markets warm up again, it looks like private equity firms are going back to work -- on big deals. According to Bloomberg.com, Apollo Global Management is prepared to offer $12 billion for Sara Lee (SLE). The transaction would also include investor C. Dean Metropoulos -- who bought Pabst Brewing in 2010 -- as well as Bain Capital and TPG.

It looks like this is a viable offer even though a strategic buyer is interested (which often can justify a higher valuation). This is JBS SA, a beef processor based in Brazil. An acquisition would certainly have lots of synergy, creating a vertical operation. Interestingly enough, JBS may seek the help of the Blackstone Group (BX).

Analyst Upgrades

• Large Cap Pharmaceuticals sector upgraded to Overweight at Wells Fargo.
• Archer Daniels (ADM) upgraded to Outperform from Neutral at Credit Suisse.
• Cypress Semi (CY) upgraded to Buy from Neutral at UBS.
• MFA Financial (MFA) upgraded to Buy from Hold at Jefferies.
• Blackstone (BX) upgraded to Buy from Hold at Jefferies.
• Comerica (CMA) upgraded to Hold from Sell at Citigroup.
• Dollar Tree (DLTR) upgraded to Overweight from Equal Weight at Morgan Stanley.
• NuVasive (NUVA) upgraded to Outperform from Market Perform at Leerink.
• Cogdell Spencer (CSA) upgraded to Buy from Hold at Jefferies.
• Hersha Hospitality (HT) upgraded to Hold from Underperform at Jefferies.
• G&K Services (GKSR) upgraded to Outperform from Neutral at RW Baird.
• Graham Packaging (GRM) upgraded to Buy from Neutral at Goldman.
• Shaw (SJR) upgraded to Neutral from Underperform at BofA/Merrill.

Since early September, shares of the major private equity firms Blackstone Group (BX) and KKR & Co. (KKR) have seen strong gains. Of course, part of the reason has been the bull move. But at the same time, the prospects for private equity are looking brighter. In fact, the upcoming year is shaping up to be strong for public offerings.

According to a report from Bloomberg.com, it looks like private-equity backed deals will account for roughly half the volume. And they will generally be massive transactions. Some that are on deck include HCA Holdings, Nielsen Holdings and Kinder Morgan.

Beckman Coulter (BEC), a top medical diagnostic instruments company, has been public over 20 years. But it looks like its days of independence may soon be over. According to a report in the Wall Street Journal, Beckman is in the process of selling itself. So far in today's trading, the shares are up 27% to $72.57, with the market cap at about $5 billion.

Beckman's products span many categories like biomedical testing and lab automation. The installed base is roughly 200,000. In fact, a large portion of the revenues come from recurring sources (such as refilling supplies for the machines). In other words, Beckman has sturdy cash flow stream.

Analyst Upgrades

• Piper Jaffray upgraded Edwards Lifesciences (EW) to overweight from neutral and raised its target price for shares to $77 from $53 after The New England Journal of Medicine reported the company's PARTNER Trial met primary endpoints.
• UBS upgraded Endo Pharmaceuticals (ENDP) to buy from neutral and raised its price target to $36 from $25. UBS is positive on Endo's creative strategic deals and believes the switch to Opana TRF from Opana ER will be easy. Additionally, the analyst believes pipeline expectations are very low.
• BMO Capital upgraded Nvidia (NVDA) to outperform from market perform based on expectations that share loss in the core GPU business will stop, Tegra momentum and valuation. The firm raised its price target to $16 from $9.
• FirstEnergy (FE) and Allegheny Energy (AYE) were upgraded to outperform from neutral at Credit Suisse.
• Mylan (MYL) was upgraded to conviction buy from buy at Goldman. Warner
• Chilcott (WCRX) was upgraded to overweight from equal weight at Morgan Stanley.

Analyst upgrades:

• Bernstein upgraded Hospira (HSP) to Outperform from market Perform based on valuation, expectations that the company will be able to fix manufacturing issues quickly, and views Propolfol and biosimilars as underappreciated. The firm has a $63 price target on the stock.
• Citigroup upgraded eBay (EBAY) to Buy from Hold citing valuation and improvements to Marketplace. The firm keeps a $28 price target for shares.
• Deutsche Bank upgraded Coca-Cola Femsa (KOF) to Hold from Sell citing lessening acquisition risk and raised its target for shares to $66 from $61.
• Blackstone (BX) and Simon Property (SPG) were upgraded to Conviction Buy from Buy at Goldman.
• BreitBurn Energy (BBEP) was upgraded to Outperform from Market Perform at Wells Fargo.
• SL Green Realty (SLG) was upgraded to Buy from Neutral at BofA/Merrill.

Analyst Upgrades

• Berstein upgraded Diamond Offshore (DO) to market perform from underperform based on valuation. The firm has a $69 price target on the stock.
• Jefferies upgraded Patterson-UTI Energy (PTEN) to buy from hold, citing leverage to higher land rig pricing. The firm raised its price target to $21 from $17.
• Wunderlich upgraded Renasant (RNST) to buy from hold following the company's acquisition of Crescent Bank. The firm raised its target for shares to $20 from $15.
• AT&T (T) was upgraded to buy from hold at Deutsche Bank.
• Blackstone (BX) was upgraded to buy from neutral at BofA/Merrill.
• Scripps Networks (SNI) was upgraded to overweight from equal weight at Morgan Stanley.

If you have been shying away from the Blackstone Group (BX) because its stock has fallen from a high above $17 in October 2009 to a low just above $9 earlier this month, you are not alone. However, it is time to take a second look at this private-equity firm gone public.

Blackstone, citing a rebound in the value of its real estate portfolio, surprised Wall Street today by beating analyst expectations by 2 cents per share. The consensus estimate had come in at 16 cents, and Blackstone posted earnings of 18 cents per share on $205 million in profit.

This may be the catalyst the stock needed to help it complete an inverted head-and-shoulders pattern on its chart and send it climbing higher.

Here's a story about the psychological dynamic of stock market trading. When trading we work from preconceived assumptions, i.e. are we bullish or bearish. Usually we find traders on both sides of a market.

Byron Wien of the Blackstone Group (BX) is in the bullish camp. Here are some of his assumptions: